Desipramine ( DrugBank: Desipramine )
2 diseases
ID | Disease name (Link within this page) | Number of trials |
---|---|---|
120 | Hereditary dystonia | 1 |
156 | Rett syndrome | 1 |
120. Hereditary dystonia
Clinical trials : 26 / Drugs : 19 - (DrugBank : 3) / Drug target genes : 2 - Drug target pathways : 2
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT03726996 (ClinicalTrials.gov) | January 14, 2019 | 29/10/2018 | Desipramine in Infantile Neuroaxonal Dystrophy (INAD). | Novel Off-label Use of Desipramine in Infantile Neuroaxonal Dystrophy: Targeting the Sphingolipid Metabolism Pathway to Reduce Accumulation of Ceramide. | Infantile Neuroaxonal Dystrophy | Drug: Desipramine | Duke University | NULL | Terminated | 3 Years | 17 Years | All | 4 | Phase 4 | United States |
156. Rett syndrome
Clinical trials : 44 / Drugs : 61 - (DrugBank : 23) / Drug target genes : 57 - Drug target pathways : 83
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT00990691 (ClinicalTrials.gov) | February 17, 2009 | 6/10/2009 | Pilot Study of the Effects of the Desipramine on the Neurovegetative Parameters of the Child With Rett Syndrome | Pilot Study of the Effects of the Desipramine on the Neurovegetative Parameters of the Child With Rett Syndrome | Rett Syndrome | Drug: Administration of a high dose of desipramine;Drug: Administration of a low dose of desipramine;Drug: Administration of a placebo | Assistance Publique Hopitaux De Marseille | NULL | Completed | 4 Years | 18 Years | Female | 36 | Phase 2 | France |